Pattern 4

Choline/Betaine Availability and BHMT-Dependent Remethylation

Your homocysteine is high.
Is the choline-betaine pathway actually limiting?

Your homocysteine is elevated.

Folate and vitamin B12 may appear adequate, yet the result remains unchanged.

Perhaps a genetic report highlights BHMT, PEMT, or CHDH variants. Perhaps an online calculator estimates that you need the equivalent of several egg yolks every day. Or perhaps TMG lowered your homocysteine, improved your energy, or made you feel anxious, depressed, overstimulated, or unable to sleep.

The common explanation is:

“TMG bypasses MTHFR, so a response proves that the BHMT pathway was impaired.”

The real interpretation is more limited.

Choline can be converted into betaine. Betaine can donate a methyl group to homocysteine through the enzyme betaine-homocysteine methyltransferase, or BHMT. Human intervention studies show that betaine can lower plasma homocysteine.

However, there is no validated clinical test that diagnoses: “Choline/Betaine-Dependent Remethylation Impairment.”

Routine laboratory tests do not measure real-time BHMT flux. A common BHMT variant does not show that the enzyme is blocked. Low plasma choline does not prove that all tissues are choline deficient. A fall in homocysteine after TMG does not establish why homocysteine was elevated.

This pattern therefore asks a more useful question:

Do the dietary, laboratory, genetic, and response findings make limited choline or betaine availability a plausible contributor to elevated homocysteine, or is another explanation more convincing?

Back to Pattern Navigator

EXPLORE THIS PATTERN 01 / 08

Does your pattern fit?

When choline or betaine may be relevant.

How closely does your pattern fit?

Genetic and laboratory pattern	What this combination may suggest
677TT + elevated homocysteine + low or marginal riboflavin status	This is the strongest configuration supporting a possible riboflavin-sensitive MTHFR component
677TT + elevated homocysteine + adequate folate and B12 + preserved kidney function	Riboflavin may be one remaining modifiable factor, particularly when intake or status is low
677TT + elevated homocysteine + clearly low folate	Folate may remain the more immediate limitation; folate and riboflavin-related factors can coexist
677TT + elevated homocysteine + evidence of B12 deficiency	The B12-dependent methionine synthase step may be more important than riboflavin-sensitive MTHFR function
677TT + normal homocysteine + adequate folate and B12	The genotype is present, but a clinically meaningful remethylation phenotype has not been demonstrated
677TT + normal homocysteine + nonspecific symptoms	There is not enough evidence to attribute the symptoms to MTHFR or to predict a riboflavin response
677CT + elevated homocysteine	The direct TT-specific riboflavin evidence should not be transferred automatically; other causes deserve careful consideration
A1298C without 677TT	This is not the same FAD-sensitive pattern and should not be interpreted using the 677TT trial evidence
677TT + high homocysteine despite substantial riboflavin exposure	Riboflavin becomes less convincing as the main remaining limitation
677TT + hypertension	A genotype-specific riboflavin response has been proposed, but current blood-pressure evidence remains uncertain
Homocysteine falls after low-dose riboflavin under otherwise stable conditions	This supports a riboflavin-sensitive contribution but does not establish that MTHFR was the only cause
A negative reaction to riboflavin or R5P	The reaction may be clinically relevant, but it does not prove "overmethylation" or excessive MTHFR activation

The combinations below are educational examples. They are not diagnostic criteria, and the same laboratory result may have several causes.

The limited-availability hypothesis becomes more plausible when:

fasting homocysteine is reproducibly elevated;
folate and vitamin B12 have been assessed adequately;
kidney and thyroid function do not provide a stronger explanation;
dietary choline or betaine exposure is plausibly low;
plasma betaine is low or marginal under interpretable conditions;
liver function does not make the pattern difficult to interpret;
an objective homocysteine response occurs after a documented intervention while other relevant variables remain stable.

The more of these features align, the stronger the case for a betaine-responsive contribution.

Even then, the available evidence does not create a formal diagnosis of BHMT impairment.

EXPLORE THIS PATTERN 02 / 08

How the BHMT Pathway Works

How betaine remethylates homocysteine.

How the BHMT Pathway Works?

How betaine remethylates homocysteine.

Homocysteine is a normal intermediate in methionine metabolism.

It can be directed into two broad pathways:

remethylation back to methionine;

transsulfuration toward cystathionine and downstream sulfur metabolites.

There are two major remethylation routes relevant to this pattern.

Folate- and B12-dependent remethylation

Methionine synthase converts homocysteine into methionine using:

5-MTHF as the methyl donor;
vitamin B12 as a cofactor.

This pathway operates broadly across tissues.

Betaine-dependent remethylation

BHMT converts:

betaine + homocysteine → dimethylglycine + methionine

In this reaction:

betaine provides the methyl group;
homocysteine becomes methionine;
dimethylglycine, or DMG, is produced;
BHMT functions as a zinc-dependent enzyme.

BHMT expression is concentrated particularly in the liver and kidney.

This tissue distribution matters.

5-MTHF as the methyl donor;
vitamin B12 as a cofactor.

betaine + homocysteine

Methionine synthase

BHMT

methionine

dimethylglycine + methionine

BHMT expression is concentrated particularly in the liver and kidney.

A reduction in plasma homocysteine after betaine can show that hepatic and renal betaine-dependent remethylation contributed to handling the circulating homocysteine pool.

It does not demonstrate that:

folate-dependent remethylation has been restored;
MTHFR activity has normalized;
vitamin B12 is no longer relevant;
remethylation has increased equally in every tissue;
brain methylation has been corrected;
neurotransmitter metabolism has been normalized;
every symptom was caused by homocysteine.

Evidence: [A1, B1, B2].

Where does betaine come from?

Betaine can enter the pathway through two main routes.

Dietary betaine

Betaine is naturally present in foods, including:

wheat products;
wheat bran and wheat germ;
beets;
spinach;
quinoa;
selected grains and plant foods.

The amount varies considerably according to the food, agricultural conditions, processing, and serving size.

Oxidation of choline

Choline can be oxidized in two steps:

choline → betaine aldehyde → betaine

The conversion is effectively irreversible.

Once choline has been converted into betaine, that molecule is no longer available for:

phosphatidylcholine synthesis;
acetylcholine synthesis;
sphingomyelin synthesis;
other structural choline functions.

Dietary betaine

betaine

choline → betaine aldehyde → betaine

This is why choline and betaine overlap, but are not interchangeable.

Betaine can support the methyl-donor function of choline.

It cannot replace all the other biological roles of choline.

Does TMG really “bypass MTHFR”?

The phrase is partly useful and partly misleading.

What it can mean

Betaine provides a methyl group to homocysteine through BHMT without requiring:

MTHFR-generated 5-MTHF;
vitamin B12-dependent methionine synthase for that specific reaction.

In this limited sense, BHMT provides an alternative route around the folate-dependent remethylation reaction in tissues where BHMT is active.

What it does not mean

TMG does not:

repair an MTHFR variant;
produce 5-MTHF;
replenish the folate pool;
correct a methylfolate trap;
replace vitamin B12;
restore folate-dependent reactions in all tissues;
prove that MTHFR was responsible for elevated homocysteine;
establish normal methylation in the brain;
make folate or B12 assessment unnecessary.

A lower plasma homocysteine result shows that the alternative route can respond to additional betaine.

It does not establish why the original elevation occurred.

Interpretive takeaway

TMG can provide an alternative substrate for homocysteine remethylation. It does not restore the entire folate-B12 pathway.

EXPLORE THIS PATTERN 03 / 08

How to Read the Laboratory Pattern

What the main marker combinations may suggest.

How to read the laboratory pattern?

Does elevated homocysteine prove that choline or betaine is inadequate?

No.

Homocysteine is influenced by:

folate;
vitamin B12;
vitamin B6;
riboflavin;
kidney function;
thyroid function;
age;
smoking;
alcohol exposure;
methionine intake;
physical activity;
selected medications;
liver and metabolic disease;
rare inherited disorders;
several factors acting together.

Low choline or betaine availability is therefore one possible contributor, not the default explanation.

The hypothesis becomes more relevant when:

folate is adequate;
B12 deficiency is not strongly supported;
kidney function is preserved;
hypothyroidism is not a better explanation;
dietary exposure is limited;
plasma betaine is low or marginal;
homocysteine responds reproducibly to betaine under stable conditions.

It becomes less convincing when:

folate deficiency is clear;
B12 deficiency is clear;
eGFR is reduced;
liver disease substantially alters methionine metabolism;
homocysteine is consistently normal;
dietary exposure and plasma betaine are adequate;
substantial betaine exposure does not change the objective pattern;
the interpretation rests mainly on symptoms or SNP reports.

Homocysteine

Is the measurable phenotype reproducibly elevated?

Folate and B12

Are stronger remethylation limitations present?

Kidney and thyroid function

Do they provide a stronger explanation?

Dietary exposure and plasma betaine

Is limited availability plausible?

Low choline or betaine availability is therefore one possible contributor, not the default explanation.

Homocysteine is normal. Does a genetic result justify intervention?

A BHMT, PEMT, or CHDH variant can provide biological context.

It does not automatically create a supplement requirement.

When the available findings include:

normal fasting homocysteine;
no evidence of choline deficiency;
no relevant liver or muscle abnormality;
no established nutritional inadequacy;
only nonspecific symptoms;
a common genetic variant,

there is not enough evidence to diagnose BHMT-dependent remethylation impairment.

Normal homocysteine does not show that every aspect of choline metabolism is optimal.

Choline still has essential structural, hepatic, neurological, and developmental functions.

However, the absence of a compatible homocysteine phenotype means that the main measurable feature of this pattern has not been demonstrated.

Interpretive takeaway

A variant may identify a potential difference in metabolism. It does not show that a pathway is currently failing.

Homocysteine fell after TMG. What can reasonably be concluded?

A fall in homocysteine supports the conclusion that circulating homocysteine was responsive to additional betaine.

The response is more interpretable when:

fasting homocysteine was elevated on more than one occasion;
the betaine product, dose, and duration were documented;
folate and B12 exposure remained stable;
kidney and thyroid function remained stable;
diet did not change substantially;
no new homocysteine-lowering supplement was introduced;
the same laboratory and comparable testing conditions were used.

The response does not prove that:

the person was betaine deficient;
BHMT was genetically impaired;
BHMT was the main bottleneck;
dietary choline was inadequate;
MTHFR was bypassed in every tissue;
methylation was globally restored;
the original homocysteine elevation had only one cause;
symptoms were caused by elevated homocysteine;
the same exposure should continue indefinitely;
a larger dose would provide a better outcome.

Homocysteine also has biological and analytical variability.

A controlled before-and-after comparison is stronger than a single result, but it remains evidence of responsiveness, not proof of a unique diagnosis.

Homocysteine did not fall. What might that mean?

Several explanations are possible.

1. Choline or betaine availability was not the main limitation

The pathway may already have had adequate substrate.

2. Folate remains inadequate

Betaine-dependent remethylation may not fully compensate for limited folate-dependent metabolism.

3. Vitamin B12-dependent methionine synthase remains limited

A person can have more than one remethylation limitation.

4. Kidney function is contributing

Reduced renal function can maintain elevated homocysteine despite changes elsewhere in the network.

5. Thyroid, medication, smoking, alcohol, or metabolic factors remain active

The pattern may be mixed.

6. The baseline result was not reproducible

A small apparent elevation may reflect ordinary variation, nonfasting conditions, recent diet, or laboratory differences.

7. The exposure was not clearly documented

Products can differ in:

actual betaine content;
serving size;
salt form;
added ingredients;
adherence;
timing.

8. Several interventions were introduced together

If TMG, choline, methylfolate, B12, B6, creatine, and diet changed simultaneously, the result cannot be assigned to one factor.

9. The expected outcome was a symptom rather than homocysteine

A product may change homocysteine without improving:

fatigue;
anxiety;
mood;
sleep;
cognition;
exercise tolerance;
gastrointestinal symptoms.

Interpretive takeaway

Failure of the objective marker to change should weaken or complicate the original substrate-limitation hypothesis.

It does not automatically establish a need for:

more TMG;
a different choline form;
methylfolate;
SAMe;
additional methyl donors;
a larger supplement stack.